🇺🇸 FDA
Patent

US 11964024

B7H4-targeted antibody-drug conjugates and methods of use thereof

granted A61KA61K2039/505A61K47/6803

Quick answer

US patent 11964024 (B7H4-targeted antibody-drug conjugates and methods of use thereof) held by Mersana Therapeutics, Inc. expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Mersana Therapeutics, Inc.
Grant date
Tue Apr 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61K, A61K2039/505, A61K47/6803, A61K47/68031, A61K47/6807